Objective:To observe the effects of celastrol (CSL) on the angiogenesis after cerebral ischemia, and discuss its neuroprotection effects after cerebral ischemia. Methods80 SD rats were randomly divided into the 24 h-treatment group and 7 d -treatment group, then sub-divided into the sham operation group, reagent control group, CSL groups with low- (0.5 mg/kg), middle- (2 mg/kg) and high-dose (5 mg/kg), 8 rats in each group. The sham operation group was performed the operation but without the ischemia state. The rat model of middle cerebral artery occlusion was established in the other groups. The first-time intragastric administration was conducted after ischemia for 90 minutes and reperfusion for 30 minutes, and the rats were treated with CSL at corresponding dose once a day. The rat behavior was evaluated and the brain tissue section staining was used to evaluate the degree of cerebral ischemia reperfusion injury in rats. The IL-1β content in brain tissue was detected, and the change on cell apoptosis rate was observed. The microvessel density of cerebral cortex was observed by immunohistochemical staining, and the contents of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) were detected by ELISA.  Results:①There were statistically significant differences on all indicators between the intervention group and the corresponding sham operation group(P<0.05). ②For the comparison of neurological function score, infarct volume, apoptosis rate and VEGF and MMP-9 levels, at the same timepoint, there were statistically significant differences between the reagent control group and CSL groups with middle- and high-dose(P<0.05), and there were statistically significant differences between the middle- and high-dose group(P<0.05). ③Compared with the reagent control group at the same timepoint, the positive rate of CD31 was decreased in the CSL groups with middle- and high-dose(P<0.05). For the comparison between 24 h-treatment group and 7 d-treatment group, there was statistically significant difference on the positive rate of CD31 in the CSL groups with middle-and high-dose(P<0.05). ④In the 7 d-treatment groups, there was statistically significant difference on IL-1β level between the reagent control group and CSL groups with different doses(P<0.05). In the 24 h-treatment groups and 7 d -treatment groups, there was statistically significant difference on IL-1β level among the different doses groups(P<0.05).  Conclusion:Within certain dose, there are opposite effects of CSL on cerebral ischemia-reperfusion in acute period, that is the neuroprotection and the inhibition on angiogenesis through anti-inflammation and anti-apoptosis. And its inhibitory effect on angiogenesis may be more significant over time. In the acute period of cerebral ischemia, the effects of CSL in inhibiting inflammatory factors and alleviating cell apoptosis are dominant, which is not affected by its inhibition on angiogenesis.